Key Points
- COO Stephen Hill sold 1,236 shares of Lyell on Feb. 11 at an average price of $23.39 for ~$28,910, leaving him with 17,795 shares (a 6.49% reduction in his holding valued at about $416,225).
- Clustered insider selling occurred on Feb. 10–11 (including CEO Lynn Seely, COO Stephen Hill, Gary K. Lee and VP Veronica Sanchez Bulis), a pattern that can weigh on investor sentiment despite personal or diversification reasons.
- Clinical milestone: Lyell dosed the first patient in PiNACLE, a Phase 3 head‑to‑head CAR‑T trial (rondecabtagene autoleucel vs. liso‑cel/axi‑cel) in 2L large B‑cell lymphoma, a meaningful clinical and regulatory de‑risking step if the program advances.
Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) COO Stephen Hill sold 1,236 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the transaction, the chief operating officer owned 17,795 shares in the company, valued at $416,225.05. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Lyell Immunopharma Price Performance
Lyell Immunopharma stock opened at $25.38 on Friday. The business has a 50 day simple moving average of $27.98 and a 200-day simple moving average of $19.64. Lyell Immunopharma, Inc. has a 12 month low of $7.65 and a 12 month high of $45.00. The stock has a market capitalization of $539.07 million, a PE ratio of -1.10 and a beta of -0.14.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. As a group, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.
Institutional Trading of Lyell Immunopharma
A number of institutional investors have recently added to or reduced their stakes in LYEL. AQR Capital Management LLC grew its position in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after buying an additional 154,327 shares during the period. Marshall Wace LLP purchased a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma in the 2nd quarter worth approximately $159,000. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $210,000. Finally, Walleye Capital LLC purchased a new position in Lyell Immunopharma in the 2nd quarter valued at approximately $258,000. Hedge funds and other institutional investors own 66.05% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on LYEL shares. HC Wainwright raised shares of Lyell Immunopharma from a "neutral" rating to a "buy" rating and increased their price target for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $45.00.
Read Our Latest Research Report on LYEL
Key Headlines Impacting Lyell Immunopharma
Here are the key news stories impacting Lyell Immunopharma this week:
- Positive Sentiment: Lyell dosed the first patient in PiNACLE, a Phase 3 head‑to‑head CAR‑T trial comparing rondecabtagene autoleucel (ronde‑cel / LYL314) to liso‑cel or axi‑cel in 2L relapsed/refractory large B‑cell lymphoma — a meaningful clinical and regulatory de‑risking step if the program advances. PiNACLE Phase 3 dosing
- Neutral Sentiment: Research and institutional positioning — the stock carries a mixed analyst profile (HC Wainwright upgraded LYEL to Buy and raised its PT previously) and significant institutional ownership (~66%), which can amplify moves but doesn't change near‑term binary clinical risk. MarketBeat LYEL profile
- Negative Sentiment: Multiple insider sales this week — CEO Lynn Seely, COO Stephen Hill, insider Gary K. Lee and VP Veronica Sanchez Bulis reported sales on Feb. 10–11 that reduced their holdings (including a CEO sale of 7,455 shares on Feb. 11). Large or clustered insider selling can weigh on sentiment even if for personal/diversification reasons. SEC filings: CEO 2/11 Form 4 Gary Lee 2/11 Form 4 COO 2/11 Form 4 CEO 2/10 Form 4
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
